Incyte Finalizes $1.25B Vega Therapeutics Acquisition, Adding Phase 3 Bleeding Disorder Drug VGA039
INCY sits 74% above its 52-week low of $66.85.
Summary
Incyte has completed its acquisition of Vega Therapeutics for $1.25 billion upfront, with potential for an additional $750 million in sales milestones. This follows the initial announcement of the acquisition on June 8th. The deal adds VGA039, a novel Phase 3 monoclonal antibody for von Willebrand disease (VWD), to Incyte's hematology portfolio. VGA039 has received multiple FDA designations, including Breakthrough Therapy, and is a potential first-in-class, once-monthly subcutaneous prophylactic therapy for VWD, significantly strengthening Incyte's late-stage pipeline. The transaction will be recorded as a one-time R&D expense in Q3 2026.
At the time of this announcement, INCY was trading at $116.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3B. The 52-week trading range was $66.85 to $118.69. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.